Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV Low-grade malignant non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1590-1596

  Hagenbeek, Anton ^a   Eghbali, Houchingue ^b   Monfardini, Silvio ^b   Vitolo, Umberto ^b   Hoskin, Peter J ^b   De Wolf Peeters, Christiane ^b   MacLennan, Ken ^b   Staab Renner, Elvira ^b   Kalmus, Joachim ^b   Schott, Astrid ^b   Teodorovic, Ivana ^b   Negrouk, Anastassia ^b   Van Glabbeke, Martine ^b   Marcus, Robert ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; COP PROTOCOL 2; DRUG DERIVATIVE; VIDARABINE PHOSPHATE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSCIOUSNESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; COMPARATIVE STUDY; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROSPECTIVE STUDIES; VIDARABINE PHOSPHATE; VINCRISTINE;

EID: 33645730985     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.7952     Document Type: Article

References (37)

1. Portlock CS: Management of the low-grade non-Hodgkin's lymphomas. Semin Oncol 17:51-59, 1990
2. Lister TA: The management of follicular lymphoma. Ann Oncol 2:131-135, 1991 (suppl 2)
3. Morrison VA, Peterson BA: Combination chemotherapy in the treatment of follicular low-grade lymphoma. Leuk Lymphoma 10:29-33, 1993 (suppl)
4. Santoro A, Balzarotti M, Tondini C, et al: Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 10:519-525, 1999
5. Brereton HD, Young RC, Longo DL, et al: A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non-Hodgkin's lymphoma. Cancer 43: 2227-2231, 1979
6. Meerwaldt JH, Carde P, Burgers JM, et al: Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radiat Oncol Biol Phys 21:1167-1172, 1991
7. Hagenbeek A, Carde P, Meerwaldt JH, et al: Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 16:41-47, 1998
8. Arranz R, Garcia-Alfonso P, Sobrino P, et al: Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization. J Clin Oncol 16:1538-1546, 1998
9. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
10. Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003
11. Hiddemann W, Unterhalt M, Pott C, et al: Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 20:28-31, 1993
12. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
13. Gregory SA, Parameswaran, Venugopal P, et al: Safety and efficacy of fludarabine and mitoxantrone with rituximab consolidation in untreated advanced low grade Non-Hodgkin's lymphoma (LG-NHL). Blood 98:605a, 2001 (abstr 2534)
14. Frewin R, Turner D, Tighe M, et al: Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 104:612-613, 1999
15. Zinzani PL, Magagnoli M, Moretti L, et al: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 18: 773-779, 2000
16. Pigaditou A, Rohatiner AZ, Whelan JS, et al: Fludarabine in low-grade lymphoma. Semin Oncol 20:24-27, 1993
17. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
18. Klasa RJ, Meyer RM, Shustik C, et al: Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 20:4649-4654, 2002
19. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2121, 1982
20. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Hochster H, Weller E, Ryan T, et al: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 23:556, 2004 (suppl, abstr 6502)
22. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
23. Zinzani PL, Pulsoni A, Perrotti A, et al: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as frontline treatment for patients with follicular lymphoma. J Clin Oncol 22:2654-2661, 2004
24. Gregory SA, Venugopal P, Adler S, et al: Combined fludarabine, mitoxantrone, and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin's lymphoma (LGNHL). Blood 100:362a, 2002 (abstr 1401)
25. Zinzani PL: A randomised trial of fludarabine versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Ann Oncol 13:57, 2002 (suppl 2, abstr 185)
26. Hiddemann W, Forstpointner R, Fiedler F, et al: The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantle cell lymphomas (MCL): Results of a prospective randomized comparison of the German Low Grade Study Group (GLSG). Blood 98:844a, 2001 (abstr 3507)
27. Hiddemann W, Dreyling M, Unterhalt M: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 30:16-20, 2003
28. Vitolo U, Boccomini C, Astolfi M, et al: Chemoimmunotherapy with fludarabine + mitoxantrone + dexamethasone (FND) and rituximab in indolent non-Hodgkin's lymphoma (NHL): A pilot study to evaluate feasibility, safety, clinical and molecular response. Blood 98:252b, 2001 (abstr 4739)
29. Tuscano J, Lara PN, O'Donnell RT, et al: Safety and efficacy of a modified fludarabine/cyclophosphamide combination in patients with relapsed/ refractory CLL and IgNHL. Blood 98:294b, 2001 (abstr 4922)
30. Flinn IW, Byrd JC, Morrison C, et al: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000
31. Montoto S, Lopez-Giullermo A, Domingo-Domenech E, et al: Fludarabine cyclophosphamide and mitoxantrone (FCM) regimen as first line therapy in younger patients with advanced stage follicular lymphoma (FL). Ann Oncol 13:57, 2002 (abstr 184)
32. Santini G, Nati S, Spriano M, et al: Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 86:282-286, 2001
33. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
34. McMillan A, Cunningham D, Hancock B, et al: Fludarabine, adriamycin, and dexamethasone (FAD) in newly diagnosed stage III/IV follicular lymphoma: A phase II study by the British National Lymphoma Investigation. Ann Oncol 13:56, 2002 (abstr 182)
35. Gordon LI, Witzig T, Molina A, et al: Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5:98-101, 2004
36. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005
37. Hagenbeek A: Future trends in radioimmunotherapy. Semin Oncol 32:S57-S62, 2005 (suppl)